Pattern is a North American immunotherapy company whose systemically-administered TLR4 agonist activates the innate immune system, to address cancers and infectious diseases. Its newly-patented P2PAR product is the next generation of a prior product developed by Pattern principals and approved in ex-US jurisdictions. Pattern has ongoing collaborations with MD Anderson Cancer Center (MDACC) and Massachusetts General Hospital, and plans to commence a Phase 1b clinical study at MDACC in solid tumors in late 2022.

Pattern Pharma Logo



Event details

Date: June 13 - 16, 2022

Event contact

Patricia Cosgrove
Area Director
USA: Life Sciences


26 in total